49MO Updated progression-free survival (PFS) in patients (pts) with newly diagnosed advanced ovarian cancer (OC) treated with rucaparib (RUC) in ATHENA-MONO

Journal article

Open access

Peer reviewed

R. Kristeleit, D. O'Malley, M-C. Lim, I. McNeish, T.J. Herzog, M. Wilson, T.N. Fehm, R.L. Coleman, T. Van Gorp, A.M. Oza, …

ESMO open, Vol.9, p.103556

06/2024

Files and links (1)

url

https://doi.org/10.1016/j.esmoop.2024.103556View

Published (Version of record) Open

3 Record Views

Title: 49MO Updated progression-free survival (PFS) in patients (pts) with newly diagnosed advanced ovarian cancer (OC) treated with rucaparib (RUC) in ATHENA-MONO
Creators: R. Kristeleit - Guy's and St Thomas' NHS Foundation Trust
D. O'Malley - The Ohio State University
M-C. Lim - Swedish Institute
I. McNeish - Imperial College London
T.J. Herzog - University of Cincinnati
M. Wilson - Auckland City Hospital
T.N. Fehm - Düsseldorf University Hospital
R.L. Coleman - The US Oncology Network
T. Van Gorp - KU Leuven
A.M. Oza - Princess Margaret Cancer Centre
O. Mikheeva - Division of Gynaecological Oncology, Limited Liability Company MedPomosch, Saint Petersburg, Russian Federation
J. Buscema - Arizona Oncology
A.S. Lisyanskaya - City Clinical Oncology Center
G. Lindahl - Linköping University
B. Gao - Westmead Hospital
D. Lorusso - Humanitas University
M. Morgan - University of Pennsylvania
D. Shih - Clinical Operations, Pharmaand, New York, NY, USA
K. Fujiwara - Saitama Medical University
B.J. Monk - Gynecologic Oncology Group
Publication Details: ESMO open, Vol.9, p.103556
Publisher: Elsevier Ltd
Identifiers: 991006098390902656
Academic Unit: Obstetrics & Gynecology
Language: English
Resource Type: Journal article